PLUS THERAPEUTICS, INC. Logo

PLUS THERAPEUTICS, INC.

Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.

PSTV | US

Overview

Corporate Details

ISIN(s):
US23283K2042 (+1 more)
LEI:
Country:
United States of America
Address:
4200 MARATHON BLVD., 78756 AUSTIN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers in adults and children. The company's proprietary platform is designed to deliver a single, high-dose of radiation directly to tumors while minimizing damage to healthy tissue. This is achieved by encapsulating Rhenium radioisotopes within novel delivery systems like nanoliposomes and biodegradable microspheres. Its lead drug candidate, REYOBIQ™ (rhenium Re186 obisbemeda), targets central nervous system (CNS) cancers, including glioblastoma and leptomeningeal metastases. The company's pipeline also includes a next-generation therapy for solid organ cancers, such as liver cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PLUS THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PLUS THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PLUS THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Sensei Biotherapeutics, Inc. Logo
Developing tumor-activated biologics to stimulate a targeted immune response against cancer.
United States of America
SNSE
Senti Biosciences, Inc. Logo
Developing smart cell and gene therapies with Gene Circuits to precisely target cancer.
United States of America
SNTI
SEOUL PHARMA CO.,LTD Logo
Develops pharmaceuticals with innovative Orally Disintegrating Film (ODF) tech for global markets.
South Korea
018680
Septerna, Inc. Logo
Advancing novel small molecule GPCR medicines for endocrine, immune, and metabolic diseases.
United States of America
SEPN
SERA PROGNOSTICS, INC. Logo
Develops predictive blood tests to assess preterm birth risk and improve pregnancy outcomes.
United States of America
SERA
Seres Therapeutics, Inc. Logo
Developing live biotherapeutics from the microbiome to treat infections and immune diseases.
United States of America
MCRB
Serina Therapeutics, Inc. Logo
Developing safer, more effective drugs for neurology and cancer using polymer technology.
United States of America
SER
SEYİTLER KİMYA SANAYİ A.Ş. Logo
Manufacturer of medical tapes, wound dressings, and first aid plasters for the healthcare industry.
Türkiye
SEYKM
Shaperon Inc. Logo
Develops inflammasome inhibitors & nanobodies for inflammatory diseases and cancer.
South Korea
378800
Shattuck Labs, Inc. Logo
Clinical-stage biotech developing novel biologic medicines for inflammatory & autoimmune diseases.
United States of America
STTK

Talk to a Data Expert

Have a question? We'll get back to you promptly.